Skip to content →

Featured Strategic Initiative: Landmark Bio

Formerly known as the new center for advanced biological innovation and manufacturing (or “CABIM”), Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today’s cutting-edge research into tomorrow’s breakthrough therapies. With construction starting on the new 40,000 square-foot biomanufacturing facility at The Arsenal on the Charles in Watertown, MA, Landmark Bio plans to begin opening at the start of 2022. The initial focus of the facility will include cell and gene therapy, gene editing, and mRNA products, which offer the potential to treat or even cure diseases such as cancer, diabetes, Parkinson’s, and Alzheimer’s, among others. Harvard University has led this initiative with its partners that include leaders from Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Massachusetts Life Sciences Center.

For more information, click here.

Published in Uncategorized

Skip to toolbar